Amy Jo Jenkins named director of clinical trials administration at UAMS Winthrop P. Rockefeller Cancer Institute

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Amy Jo Jenkins was named director of the Winthrop P. Rockefeller Cancer Institute’s new Office of Clinical Trials Administration and will lead early phase clinical trials at the University of Arkansas for Medical Sciences.

Jenkins will direct early phase clinical research, including operations, staffing, trial management and execution, and business development. She will also work to improve the effectiveness of executing cancer-related research contracts and filings in partnership with other institutional offices.

Her other duties include creating and managing a quality assurance and control program within the Cancer Institute’s research efforts, and developing and maintaining standard operating procedures. She will also oversee the UAMS Winthrop P. Rockefeller Cancer Institute Network, which includes the UAMS Regional Campuses, the UAMS/Baptist Health joint venture and the Cancer Institute’s partner practices throughout Arkansas. Jenkins will identify and use opportunities to develop and expand clinical trial participation throughout the network.

Jenkins was previously chief of staff in the office of Chancellor Cam Patterson, and CEO of UAMS Health. Prior to that, Jenkins was executive director of the Translational Research Institute from 2016 to 2020, providing oversight and leadership of the institute’s daily operations. She joined TRI in 2014 as a senior project manager. She has also taught courses through the UAMS colleges of Public Health and Pharmacy as part of a program in regulatory sciences since 2012.

She first joined UAMS in 2009 as clinical research monitoring manager.

Table of Contents

YOU MAY BE INTERESTED IN

The nagging pain in Mia Sandino’s right knee set in in September 2018, and throughout her freshman year at the University of Washington, she tried to ignore it. “I was being a very naive and invincible-feeling 19-year-old,” Sandino told The Cancer Letter. “I didn’t put two and two together that this area of the knee that...

Rick Pazdur, MD, the newly appointed director for the Center for Drug Evaluation and Research at the FDA, has been described as “greyhound thin” as a result of his dedication to cycling and lifting weights in the gym each day and, for a long time, a vegetarian diet. I first met him when he was the director of the Office of Oncology Drug Products (ODP) within CDER, in 2009.
When it comes to fighting cancer today, collaboration is key. At a time when funding is uncertain, yet innovative breakthroughs are accelerating every day, it’s more important than ever for oncologists, scientists, academic researchers, and community physicians, to come together to share knowledge and gain insights about the forefront of cancer research.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login